Medical
-
Orexo has announced results from a PK study of its OX124 naloxone nasal spray in 20 healthy volunteers that compared 4 development formulations of OX124 to Narcan naloxone nasal spray. According to the company, all… Read more . . .
-
Impel NeuroPharma has announced results from a Phase 1 PK trial of INP105 intranasal olanzapine demonstrating that the intranasal formulation achieved Tmax two times faster than Zyprexa intramuscular olanzapine and ten times faster than Zyprexa… Read more . . .
-
Biotech company Stem Cell Medicine (SCM) has announced that it licensed intranasal MSC-exo technology for the treatment of autism spectrum disorder (ASD) from Ramot, the Tel Aviv University Business Engagement Center. Preclinical studies have shown… Read more . . .
-
NPXe has announced the enrollment of the first patient in a Phase 3 study of Xenex inhaled xenon gas for the treatment of post cardiac arrest syndrome (PCAS). The FDA granted Fast Track designation to… Read more . . .
-
Aradigm Corporation says that it has scheduled a meeting with the FDA to discuss results from the Phase 3 ORBIT-3 and ORBIT-4 trials of Apulmiq (formerly Linhaliq) dual release inhaled ciprofloxacin for the treatment of… Read more . . .
-
According to US-based ARS Pharmaceuticals, the company has raised $20 million in Series C financing for clinical development of its ARS-1 epinephrine nasal spray for the treatment of anaphylaxis. The financing round was led by… Read more . . .
-
Verona Pharma said that it has initiated a Phase 2 clinical trial of its RPL554 PDE3/PDE4 inhibitor DPI. The study is expected to enroll 36 patients with moderate to severe COPD and will evaluate PK,… Read more . . .
-
Insys Therapeutics says that it plans NDA submissions for both its naloxone and epinephrine nasal sprays in 2019. The company also noted the potential of regulatory submission for its inhaled dronabinol in the next few… Read more . . .
-
According to Levo Therapeutics, the Phase 3 CARE-PWS (CARbetocin Efficacy and Safety Study in PWS) trial of LV-101 intranasal carbetocin for the treatment of Prader-Willi syndrome (PWS) has begun to enroll patients. Levo acquired the… Read more . . .
-
Acerus Pharmaceuticals said that a Phase 1 trial of its intranasal formulation of tetrahydrocannabinol-rich cannabis oil in 12 healthy volunteers demonstrated that the bioavailability of TCH from the nasal formulation was 2.2 times better than… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland